Home About us Current issue Back issues Submission Instructions Advertise Contact Login   

Search Article 
  
Advanced search 
 
Saudi Journal of Kidney Diseases and Transplantation
Users online: 4656 Home Bookmark this page Print this page Email this page Small font sizeDefault font size Increase font size 
 

EDITORIAL Table of Contents   
Year : 1995  |  Volume : 6  |  Issue : 4  |  Page : 387-395
Pharmacological Approach to Therapy of Glomerulonephritis


21, Common Road, North Leigh, Oxford 0X8 6RD, England, United Kingdom

Click here for correspondence address and email
 

   Abstract 

Since glomerulonephritis is a typical inflammation, we are approaching the time when inhibitors of the mediators of inflammation will be used to modify the course of nephritides. In this category are thromboxane synthetase inhibitors and thromboxane antagonists as well as anti-leukotriene and anti-platelet activating factor agents. Corticosteroids are often limited by their side effects. Other approaches include the use of heparins, endothelin antagonists and E prostaglandins. This article presents the background knowledge to these considerations.

Keywords: Glomerulonephritis, Inflammation, Proteinuria.

How to cite this article:
Wardle E N. Pharmacological Approach to Therapy of Glomerulonephritis. Saudi J Kidney Dis Transpl 1995;6:387-95

How to cite this URL:
Wardle E N. Pharmacological Approach to Therapy of Glomerulonephritis. Saudi J Kidney Dis Transpl [serial online] 1995 [cited 2020 Jan 21];6:387-95. Available from: http://www.sjkdt.org/text.asp?1995/6/4/387/40555

   Glomerulonephritis as an Inflammation Top


Glomerulonephritis can be caused either by the deposition of circulating plasma immune complexes in the glomerular filters or much less commonly by reaction of an antibody with the glomerular basement membrane components as in Goodpasture's syndrome. In both situations there is accompanying complement activation, platelet aggregation and intra-capillary coagulation, attraction of pro-inflammatory phagocytic cells like the polymorphonuclear neutrophils (PMNs) and monocyte-macrophages as well as activation of intrinsic glomerular endothelial and mesangial cells. Details of involvement of cells and mediators in the glomeruli were assembled by Wardle in a review [1] .

How white cells accumulate at an inflam­matory site is shown in [Figure - 1]. The process is mediated by the expression of Selection or CD11/CD18 adhesion molecules on white cells and the corresponding expression of E and P selections, and of binding molecules like ICAM-1 VCAM-1, on the endothelial cells of the post-capillary venules or in glomeruli along the length of the glomerular capillaries. Initial adhesion of white cells is promoted by local release of leukotriene B4 and platelet activating factor (PAF) and then there is slower induction of the adhesion molecules by the pro-inflammatory cytokines 11-1 beta and tumor necrosis factor alpha (TNFa). Furthermore, for adhesion to be effective the endothelial cell surface heparan sulphates must first be down-regulated [2] . The complex topic of adhesion molecules has been reviewed by Springer recently [3] .

In. most forms of glomerulonephritis, the PMNs are attracted into the glomeruli first, and often they disappear as monocyte-macro­phages accumulate. The general rule about white cell activation is that it is mediated by the leukotrienes [4] , after triggering by C5a of complement, PAF and leukotriene B4, or cytokine interleukin-8. On the other hand, prostaglandins like PGE2 that is produced by cells of the glomeruli, or prostacyclin PGI2, from the vascular endothelial cells, will dampen activation of the various white cells, and also prevent the release of their cytokines. Transforming growth factor beta (TGFL) inhibits endothelial adhesiveness for PMNs [5] and thus, it helps limit the accumulation of white cells. Nitric oxide also has similar properties [6] .


   Proteinuria Top


Permeability at sites of inflammation is caused by a combination of increased local blood flow caused by vasodilator prosta­glandins and post-capillary venular con­striction and an action on inter-endothelial cell junctions caused by peptidoleukotriene LTD4 [4] . That LTD4 causes vascular per­meability, has been shown by the use of an antagonist [7] . Additionally, complement activation, and release of white cell enzymes like cathepsin G and elastase [8] and for­mation by activated white cells of reactive oxygen species [9] will lead to damage to the components of the glomerular basement membrane (GBM) so that there is proteinuria, and even leakage of red cells. Leakage of albumin is facilitated greatly by the removal of negative charges from the heparan sulphates of the endothelial cells and from the GBM by means of heparanases that originate from platelets and white cells. Normally, albumin molecules are repulsed by the negative charges on the GBM. When those charges are reduced, albuminuria occurs; of course by this time the size of the pores in the GBM is also increased.

Increased leakage of plasma protein across the glomeruli occurs when there is vaso­constriction of the efferent arterioles of the glomeruli by agents like angiotensin II [10] , thromboxane A2 [11] or leukotriene D4 [7] or PAF [12] .

[Figure - 2] shows typical physiological measurements of glomerular hemodynamics in rats in the acute stage of anti-GBM nephritis, in comparison with measurements in normal animals. Details of the procedure are given by Blantz, et al [13] . A detailed description of the findings in nephritis has been given by Badr [14]

The hemodynamic features of the acute nephritic stage are explained by the vaso­constrictor effects of leukotrienes C4-D4, acting along with angiotensin II and throm­boxane A2. When the chronic phase is reached, the arterioles dilate in response to prostaglandins PGE1 and PGI2 and so the renal blood flow increases, although the vasconstrictor action of thromboxane A2 goes on. One will understand that in the normal circulation there is a prostaglandin/ thromboxane A2 balance. At all times in nephritis the glomerular ultrafiltration coefficient, the Kf, is reduced [14] . The Kf can be restored by the use of the leukotriene C4/D4 antagonist [7].

This pathophysiological knowledge is required for understanding the mechanism of proteinuria, as in [Table - 1]. Proteinuria is determined by raised glomerular capillary hydrostatic pressure and increased glomerular permeability.


   Phospholipid Derived Mediators Top


All cell membranes are formed of a bilayer of phospholipids. At position 2 of each phospholipid is the 20 carbon atom, 4 unsaturated bond, arachidonic acid (C20:4, n-6) [15] . From arachidonic acid the body can synthesize the 20 carbon atom derivatives "eicosanoids" namely the prostaglandins, the thromboxanes and the leukotrienes. The other agent PAF-acether is a direct derivative of phospholipid [15] .


   The Prostaglandins Top


The E and I prostaglandins cause vasodi­latation of arterioles and capillaries, and generally they inhibit platelet aggregation. Yet, PGE2 that is so much involved in nephritis can enhance platelet aggregation [16] . Significantly, it facilitates proteinuria [10] . PGE2 also relaxes the mesangial cells thereby increasing the GFR. PGE2 is also known for its "cytoprotection" of tissues, and its ability to suppress local production of cytokines and growth factors [17],[18] . The one prostaglandin that is different is PGF2 alpha, for it causes vasoconstriction and it can enhance proliferation of mesangial cells [10] . Its action is thus similar to thromboxane A2 (TxA2).


   Thromboxane A2 Top


In many pathological situations TxA2 acts as a powerful vasoconstrictor and as an agent that causes platelet aggregation. One will find this in pulmonary hypertension of diverse etiologies. In the renal circulation TxA2 lowers blood flow and the GFR [11] and it causes proteinuria [19] . Thrombo­xanes mediate tubuloglomerular feedback within the kidneys [20] , and also they mediate the renal effects of angiotensin II [21] . It is of note that the intra-renal action of thromboxane induces salt retention [22] . Even more significant in the context of nephritis is the fact that thromboxanes help mesangial cell proliferation, and they promote formation of new extracelllar matrix proteins that will eventually account for glomerulo­sclerosis [23] . Thus, deposition of collagen and fibronectin around mesangial cells is promoted. So, we see that preventing thromboxane action should be a prime aim in the therapy of the nephritides. When we consider that TxA2 is involved in all of the glomerulopathies [24] , the importance of this approach is evident.


   Platelet Activating Factor (PAF) Top


This mediator is 1-0 alkyl-2 acetyl- snglycerol 3 phosphorylcholine. One will observe that like the phospholipids, its structure is based on the glycerol molecule [15] . In the kidneys, PAF causes a reduction of renal blood flow [12] and reduction of the GFR by causing mesangial cell contraction, and it causes vascular permeability and protei­nuria. It is known to be involved in nephritis [25] .


   The Leukotrienes Top


There are two main forms. Leukotriene B4 is a chemotactic agent for white cells and it activates them. In this role it is helped by PAF. Secondly, there are the peptido­leukotrienes LTC4-LTD4-LTE4 [4] . As has been emphasized, LTC4-LTD4 cause vasoconstriction of the efferent arterioles of the glomeruli and they increase vascular permeability and hence cause proteinuria [7],[14] .

Evidence that leukotrienes are important in causing cellular proliferation in nephritis, as well as, in activating white cells, comes from studies using the 5 lipoxygenase inhibitor MK 886 [26] . Zuckerman, et al have shown how a leukotriene synthetase inhibitor (lipoxygenase inhibitor) arrests mesangial cell proliferation [27] .

Other studies demonstrate a similar importance of leukotrienes for white cell activation and circulatory changes in the glomeruli in renal transplant rejection [28] .


   The HETE (Hydroxy Eicosatrienoic Acid) Molecules Top


A HETE molecule is a hydroxy eicosatrienoic acid that arises from the 5 lipoxygenase pathway. There are several of them and their actions are complex [29] . Our main consideration is that they are vasoconstrictors that aid proteinuria [30] .


   The Lipoxins Top


As described recently by Badr, early in nephritis, one will see infiltrating PMNs at a time when the 5 lipoxygenase pathway is producing large amounts of leukotrienes, both LTB4 and the peptidoleukotrienes LTC4-LTD4 [14] . Then, macrophages come in and via the 15 lipoxygenase pathyway they form 15 (S) HETE. This molecule is a precursor of lipoxin A4, whose production then increases over days and weeks. Since lipoxin A4 is a vasodilator which counteracts the actions of leukotrienes, it constitutes a counter inflammatory mediator. Lipoxin A4 then prevents chemotaxis of PMNs and so its formation helps to explain the disappear­ance of PMNs after the acute phase of nephritis.


   The Role of Endothelins Top


Endothelins are released from endothelial cells or mesangial cells and from epithelial cells by the action of cytokines and angio­tensin II. They are known for their vaso­constrictor potential, and they can cause profound reduction of renal blood flow and glomerular filtration. ET-1 contracts the mesangial cells so that there is reduction of the glomerular filtration surface area. The glomerular ultrafiltration coefficient Kf is thereby reduced [31] .

Endothelins are mitogens for endothelial cells [32] and it is probable that their action contributes to mesangial matrix formation because they release platelet derived growth factor (PDGF). Indeed, we know that endothelin gene expression is increased in models of glomerulosclerosis [33] . Further­more, an endothelin receptor antagonist has been shown to reduce the progression of lupus nephritis in NZB/W Fl mice [34] .


   Nitric Oxide Top


As endothelium derived relaxing factor, nitric oxide is a vasodilator which helps maintain glomerular blood flow [35] . By causing elevation of intracellular cyclic GMP, nitric oxide offsets vasoconstrictor influences as well as the tendency of thromboxanes to cause extracellular matrix deposition in chronically inflamed glomeruli. Nitric oxide arises also from inflammatory cells like macrophages and the mesangial cells [36] .

Unfortunately, although nitric oxide has these protective actions, it can exacerbate acute and chronic inflammation [37] . Tissue injury that results from the deposition of immune complexes is actually facilitated by nitric oxide [38] . Inhibitors of nitric oxide benefit the autoimmune glomerulonephritis of MRL-1pr mice. Yet, nitric oxide inhi­bition would not be recommended in man because that reduces salt excretion by the kidneys.


   The Therapy of Nephritis Top


1. Use of Corticosteroids

Steroids are used to treat minimal change nephrosis and SLE nephritis because they cause lymphocytolysis. Via the activation of specific endonucleases, they lead to programmed cell death (apoptosis) of those cells.

There are several important anti-inflammatory effects of steroids [Table - 2]. All this means that a trial of their use should be used in other types of nephritis. Yet, one realises that really they are best used in combination with other immunosuppressive agents because high dosage steroids alone cause so many side-effects.

The beneficial effects of steroids only last for the duration of usage. However, there is effective inhibition of cytokine release when they are administered on an alternate day basis. Most of the effects of steroids are mediated by means of intranuclear events [39] , although they also promote synthesis of cell membrane "lipocortin" which is the inhibitor of phospholipase A2 [4] . In this way, the ability of steroids to stop the synthesis of PAF and of the leukotrienes is explained.


   Reducing Proteinuria Top


Non-steroidal anti-inflammatory drugs can be used to reduce heavy proteinuria, which they do by inhibiting the production of PGE2/PGI2, so that there is constriction of the afferent arterioles of the kidneys. They can cause adverse side effects. Thus, there is the possibility of causing allergic inter­stitial nephritis or even acute renal failure. Hence, for the purpose of lessening protei­nuria, one would be better advised to try the ACE inhibitors [40] . Their action is mediated by dilatation of the efferent arterioles. Yet, there are patients who cannot tolerate the ACE inhibitors.

Many nephrologists use small dose of aspirin (75 mg per day) in order to stop thromboxane synthesis, as one might use in the prevention of pre-eclampsia. The hope is to arrest proliferation of mesangial cells and the development of glomerulosclerosis. To date there is little evidence that this objective is achieved. In fact, aspirin 75 mg per day is best combined with dipyridamole 100 mg thrice daily for its anti-oxidant effect. We know that dipyridamole prevents formation of leukotrienes and reduces proteinuria [41] . An anti-oxidant drug that has received too little attention is Probucol. This is effective for the prevention of atherosclerosis in animals [42] . Probucol stops the action of lipoxygenases. It can be used to prevent focal glomerulosclerosis [43] . Probucol could be useful in the pre­vention of diabetic nephropathy [44] . Certainly, it can be used when patients cannot tolerate the ACE inhibitors. The drug pentoxifylline (Trental) reduces proteinuria in insulin dependent and non-insulin dependent diabetics [45] . By increasing red cell deformability it may reduce glomerular hydraulic pressure. Since pentoxifylline is a phosphodiesterase inhibitor like aminophylline that potentiates the action of cyclic AMP in cells, it can also inhibit platelets and the activation of leuco­cytes. So it might confer additional advantage in nephritides.


   Anti-PAF Agents or Anti-leukotrienes Top


A role of PAF in experimental renal injury is well established [25] . Steroids will suppress the production of PAF and of the leukotrienes. Furthermore, specific antagonists for both PAF and the leukotrienes are now available. The only information about their application is in experimental renal disease [26],[27] . It has been shown that a PAF receptor antagonist can help preserve the remaining nephrons in damaged kidneys [46] .


   Thromboxane Antagonism Top


Inhibitors of thromboxane synthetase [Figure - 3] and antagonists for thromboxane receptors are now available [47] . Many experimental studies attest to their efficacy in the control of proteinuria and lessening of nephritis and subsequent glomerulo­sclerosis [24] . Thromboxane synthetase inhibition prolongs the survival of mice with lupus nephritis [48] .

Reports of the use of these agents in man are limited. Ideally one should use a throm­boxane synthetase inhibitor and a throm­boxane receptor antagonist in combination. One will expect lowering blood pressure and marked lessening of proteinuria. They have been used in minimal change nephrosis and in SLE nephritis and for diabetic nephropathy. The agent Ridogrel appears promising in this regard [49] .


   Vasculitis with Nephritis Top


One will know of the prednisolone plus cyclophosphamide regimens for vasculitides [50] . Monthly intravenous pulse cyclophos­phamide is certainly effective for various serious nephropathies [51] .

One can use dapsone for Henoch-Schonlein syndrome [52] , since dapsone stops neutrophil damage to tissues. Dapsone 100 mg per day in combination with pentoxifylline 400 mg thrice daily is good for serious vasculitides [53] . Another useful approach is intra­venous PGE1 therapy [54] . PGE1 can be infused daily on a long term basis [55] . Its action is to inhibit the activation of platelets, polymorphs and lymphocytes, and to reduce proteinuria [56] . It is of particular note that PGE1 will inhibit the Th-1 lymphocytes [57] that direct the delayed hypersensitivity reaction involving activated macrophages which is the basis of progre­ssive forms of nephritis [57],[58] . With all vasculitides one must bear in mind that the cause could be a drug allergy [59] .


   Other Consideration: Preventing Renal Fibrosis Top


Cyclosporin can be used for nephritides, but in view of the possibility of decline of renal function [60] that decision should be made by an expert. Certainly it can be used to good effect for lupus nephritis.

Heparins have a respectable record in the treatment of experimental nephritides [61] and they can be used in acute nephritis, SLE nephritis and rapidly progressive nephritides as well as for more chronic cases [62] . Nowadays we might prefer to use low MW heparins. Heparin suppresses the proliferation of mesangial cells [63] . Significantly heparin has been shown to suppress the release of endothelins (ET-1) and to promote moderate nitric oxide for-mation by endothelium [64] . Preservation of nitric oxide opposes the potential of thromoboxanes for causing glomerular and interstitial fibrosis.

The ACE inhibitors have the potential for reducing renal fibrosis, and this benefit will accrue if they are used for treating any hypertension associated with nephritis. They stop angiotension II exerting its pro­fibrotic influence. Also, by potentiation of bradykinin they facilitate the beneficial effects of nitric oxide.

 
   References Top

1.Wardle EN. Cells and mediators in glomerulonephritis. Nephron 1988;49:265­76.  Back to cited text no. 1  [PUBMED]  
2.Kobayashi M, himada K, Ozawa T. Human recombinant interleukin-beta- and tumor necrosis factor alpha mediated suppression of heparin-like compounds on cultured porcine aortic endothelial cells. J Cell Physiol 1990;144:383-90.  Back to cited text no. 2  [PUBMED]  
3.Springer TA. Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. Ann Rev Physiol 1995;57:827-72.  Back to cited text no. 3    
4.Wardle EN. Understanding leukotrienes. Br J Hosp Med 1986;35:382-7.  Back to cited text no. 4    
5.Gamble JR, Vadas MA. Endothelial adhesiveness for blood neutrophils is inhibited by transforming growth factor­beta. Science 1988;242:97-9.  Back to cited text no. 5  [PUBMED]  [FULLTEXT]
6.Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991;88:4651-5.  Back to cited text no. 6  [PUBMED]  [FULLTEXT]
7.Badr KF, Brenner BM, Ichikawa I. Effects of leukotriene D4 on glomerular dynamics in the rat. Am J Physiol 1987;253:239-43.  Back to cited text no. 7    
8.Johnson RJ, Lovett D, Lehrer RI, Couser WG, Klebanoff SJ. Role of oxidants and proteases in glomerular injury. Kidney Int 1994;45:352-9.  Back to cited text no. 8  [PUBMED]  
9.Shah SV. The role of reactive oxygen metabolites in glomerular disease. Ann Rev Physiol 1995;57:245-62.  Back to cited text no. 9    
10.Dunn MJ. The roles of angiotensin II and prostaglandins in the regulation of the glomerular filtration of lbumin. J Hypertens SuppI 1990;8:47-52.  Back to cited text no. 10    
11.Baylis C. Effects of administered thromboxanes on the intact normal rat kidney. Renal Physiol 1987;10:110-21.  Back to cited text no. 11  [PUBMED]  
12.Camussi G. Potential role of platelet­activating factor in renal pathophysiology Kidney Int 1986;29:469-77.  Back to cited text no. 12    
13.Blantz RC, Konnen KS, Tucker BJ. Angiotensin II effects upon the glomerular microcirculation and ultrafiltration coefficient of the rat. J Clin Invest 1976;57:419-34.  Back to cited text no. 13  [PUBMED]  [FULLTEXT]
14.Badr KF. Arachidonate cyclo-oxygenase and lipoxygenase products in the mediation of glomerular immune injury. Nephrol Dial Transplant 1991;6:662-9.  Back to cited text no. 14  [PUBMED]  
15.Wardle EN. Guide to the prostaglandins. Br J Hosp Med 1985;34:229-32.  Back to cited text no. 15  [PUBMED]  
16.Stork JE, Dunn MJ. Hemodynamic roles of thromboxane A2 and prostaglandin E2 in glomerulonephritis. J Pharmacol Exp Ther 19S5;233:672-8.  Back to cited text no. 16    
17.Homma T, Ichikawa I, Hoover RL. Prostaglandins of mesangium original inhibit mesangial cell proliferation and matrix synthesis. Kidney Int 1988;233:268A.  Back to cited text no. 17    
18.Zehner G, Disser M, Thaiss F, Wolf G, Schoeppe W, Stahl RA. The effect of prostaglandin E2 of mRNA expression and secretion of collagens I, III and IV and fibronectin in cultured rat mesangial cells. J Am Soc Nephrol 1994;4:1778-85.  Back to cited text no. 18    
19.Remuzzi G.Imberti L, Ressini M, et al. Increased glomerular thromboxane synthesis as a cause of proteinuria in experimental nephrosis. J Clin Invest 1995;75:94-101.  Back to cited text no. 19    
20.Welch WJ, Wilcox CS. Modulating role for thromboxane in the tubuloglomerular feedback response in the rat. J Clin Invest 1988;81:1843-9.  Back to cited text no. 20  [PUBMED]  [FULLTEXT]
21.Wilcox CS, Welch WJ, Snellen H. Thromboxane mediates renal hemodynamic response to infused angiotensin II. Kidney Int 1991;40:1090-7.  Back to cited text no. 21  [PUBMED]  
22.Pinzani M, Laffi G, Meacci E, Lavilla G, Cominelli F, Gentilini P. Intrarenal thromboxane A2 generation reduces the furosemide-induced sodium and water diuresis in cirrhosis with ascites. Gastroenterology 1988;95:1081-7.  Back to cited text no. 22    
23.Kohan DE. Eicosanoids: potential regulators of xtracellular matrix formation in the kidney. J Lab Clin Med 1992;120:4­6.  Back to cited text no. 23  [PUBMED]  
24.Remuzzi G, FitzGerald GA, Patrono C. Thromboxane synthesis and action within the kidney. Kidney Int 1992;41:1483-93.  Back to cited text no. 24  [PUBMED]  
25.Ortiz A, Gomez-Chiarri M, Lerma JL, Gonzalez E, Egido J. The role of platelet­activating factor (PAF) in experimental glomerular injury. Lipids 1991;26:1310-5.  Back to cited text no. 25  [PUBMED]  
26.Wu SH, Lianos EA. Modulatory effect of arachi donate 5-lipoxygenation on glomerular cell proliferation in nephrotoxic serum nephritis. J Lab Clin Med 1993;122:703-10.  Back to cited text no. 26  [PUBMED]  
27.Zuckerman AL, Stenzel KH, Suthanthiran M, Holthofer H, Schlondorff D. Modulation of mouse mesangial cell proliferation by thiourea and lipoxygenase inhibitors. Nephron 1994;66:337-43.  Back to cited text no. 27  [PUBMED]  
28.Spurney RF. Ibrahim S, Butterly D, Klotman PE, Sanfilippo F, Coffman TM. Leukotrienes in renal transplant rejection in rats. Distinct roles for leukotriene B4 and peptidoleukotrienes in the pathogenesis of allograft injury. J Immunol 1994;152:867­76.  Back to cited text no. 28    
29.Spector AA, Gordon JA, Moore SA. Hydroxyeicosatetraenoic acids (HETEs). Prog Lipid Res 1988;27:271-323.  Back to cited text no. 29  [PUBMED]  [FULLTEXT]
30.Lianos EA. Synthesis of hydroxyeicosatetraenoic acids and leukotrienes in rat nephrotoxic serum glomerulonephritis. Role of antiglomerular basement membrane antibody dose, complement, and neutrophiles. J Clin Invest 1988;82:427-35.  Back to cited text no. 30    
31.Badr KF, Murray JJ, Breyer MD, Takahashi K, Inagami T, Harris RC. Mesangial cell, glomerular and renal vascular responses to endothelin in the rat kidney. Elucidation of signal transduction pathways. J Clin Invest 1989;83:336-42.  Back to cited text no. 31    
32.Simonson MS, Dunn MJ. Endothelin peptides: a possible role in glomerular inflammation. Lab Invest 1991;64:l-4.  Back to cited text no. 32    
33.Orisio S, Benigni A, Bruzzi I, et al. Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. Kidney Int 1993;43:354-8.  Back to cited text no. 33  [PUBMED]  
34.Nakamura T, Ebihara I, Tomino Y, Koide H. Effect of a specific endothelin A receptor antagonist on murine lupus nephritis. Kidney Int 1995;47:481-9.  Back to cited text no. 34  [PUBMED]  
35.Cattell V, Cook HT. Nitric Oxide: role in the physiology and pathology of the glomerulus. Exp Nephrol 1993;l:265-80.  Back to cited text no. 35    
36.Pfeilschifter J, Kunz D, Muhl H. Nitric oxide: an inflammatory mediator of glomerular mesangial cells. Nephron 1993;64:518-25.  Back to cited text no. 36    
37.Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002-12.  Back to cited text no. 37  [PUBMED]  [FULLTEXT]
38.Mulligan MS, Hevel JM, Marietta MA, Ward PA. Tissue injury caused by deposition of immune complexes is L­arginine dependent. Proc Natl Acad Sci USA 1991;88:6338-42.  Back to cited text no. 38    
39.Barnes PJ, Adcock I. Anti-inflammatory action of steroids: molecular mechanisms. Trends Pharmacol Sci 1993;14:436-41.  Back to cited text no. 39  [PUBMED]  
40.Thomas DM, Hillis AN, Coles GA, Davies M, Williams JD. Enalapril can treat the proteinuria of membranous glomerulonephritis without detriment to systemic or renal hemodynamics. Am J Kidney Dis 1991;18:38-43.  Back to cited text no. 40    
41.De la Cruz JP, Camara S, Frutos MA, Sanchez de la Cueste F. Effect of dipyridamole with or without aspirin on urine protein excretion in patients with membranous glomerulonephritis. Eur J Clin Pharmacol 1992;43:307-9.  Back to cited text no. 41    
42.Parthasarathy S. Evidence for an additional intracellular site of action of probucol in the prevention of oxidative modification of low density lipoprotein. Use of a new water­soluble probucol derivative. J Clin Invest 1992;89:1618-21.  Back to cited text no. 42    
43.Hirano T, Morohoshi T. Treatment of hyperlipi-demia with probucol suppresses the development of focal and segmental glomerulosclerosis in chronic aminonucleoside nephrosis. Nephron 1992;60:443-7.  Back to cited text no. 43  [PUBMED]  
44.Wardle EN. Vascular permeability in diabetics and implications for therapy. Diabetes Res Clin Pract 1994;23:135-9.  Back to cited text no. 44  [PUBMED]  
45.Guerrero-Romero F, Rodriguez-Moran M,Paniagua-Sierra JR, Garcia Bulnes G, Salas-Ramirez M, Amato D. Pentoxifylline reduces proteinuria in insulin dependent and non insulin dependent diabetic patients. Clin Nephrol 1995;43:116-21.  Back to cited text no. 45    
46.Thaiss F, Mihatsch MJ, Oberle G, Haberstroh U, Brecht HM, Stahl RA. Platelet-activating factor receptor antagonist improves renal function and glomerular lesions in renal ablation. J Lab Clin Med 1994;124:775-81.  Back to cited text no. 46  [PUBMED]  
47.Gresele P, Deckmyn H, Nenci GG, Vermylen J. Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in throm­botic disorders. Trends Pharmacol Sci 1991;12:158-63.  Back to cited text no. 47  [PUBMED]  
48.Salvati P, Lamberti E, Ferrario R, et al. Thromboxane synthase inhibition prolongs survival in murine lupus nephritis. Kidney Int 1995;47:1168-75.  Back to cited text no. 48  [PUBMED]  
49.Weber C, Beetens JR, Tegtmeier F, et al. Ridogrel inhibits systemic and renal formation of thromboxane A2 and antagonizes platelet thromboxane A2/prostaglandin endoperoxide receptors upon chronic administration to man. Thromb Haemost 1992;68:214-20.  Back to cited text no. 49  [PUBMED]  
50.Gordon M, Luqmani RA, Adu D, et al. Relapses in patients with a systemic vasculitis. Q J Med 1993;86:779-89.  Back to cited text no. 50  [PUBMED]  [FULLTEXT]
51.McCune WJ, Golbus J, Zeldes W, Bohlke P, Dunne R, Fox DA. Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med 1988;318:1423-31.  Back to cited text no. 51  [PUBMED]  
52.Hoffbrand BI. Dapsone in Henoch­Schonlein purpura-worth a trial. Postgrad Med J 1991;67:961-2.  Back to cited text no. 52  [PUBMED]  
53.Nurnberg W, Grabbe J, Czarnetzki BM. Synergistic effects of pentoxifylline and dapsone in leucocytoclastic vasculitis (letter). Lancet 1994;343:491.  Back to cited text no. 53    
54.Lim CY. Improvement in steroid and immunosuppressive drug resistant lupus nephritis by intravenous PGE1 therapy.Nephron 1990;53:258-64.  Back to cited text no. 54    
55.Nagayama Y, Namura Y, Tamura T. Muso R. Beneficial effect of prostaglandin El in three cases of lupus nephritis with nephrotic syndrome. Ann Allergy 1988;61:289-95.  Back to cited text no. 55    
56.Wolf S, Erley CM, Berger ED, et al. Effects of prostaglandin El on proteinuria, glomerular permeability and renal haemodynamics in patients with chronic glomerulonephritis. Kidney Int 47, 1007 (Abs).  Back to cited text no. 56    
57.Wardle EN. Neutralizing inflammatory cytokines in nephritis. Nephron 1995;69:223-7.  Back to cited text no. 57  [PUBMED]  
58.Gold KN, Weyand CM, Goronzy JJ. Modulation of helper T cell function by prostaglandins. Arthritis Rheum 1994;37:925-33.  Back to cited text no. 58  [PUBMED]  
59.Jain KK. Drug induced cutaneous vasculitis. Adverse Drug React Toxicol Rev 1993;12(4):263-76.  Back to cited text no. 59    
60.Meyrier A, Noel LH, Auriche P, Callard P. Long term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Kidney Int 1994;45:1446-56.  Back to cited text no. 60    
61.Wardle EN. Altering the course of proliferative nephritides: the challenge of the 1990's. J Int Med Res 1992;20:361-70.  Back to cited text no. 61  [PUBMED]  
62.Cade JR, DeQuesada AM, Shires DL, et al. The effect of long term high dose heparin treatment on the course of chronic proliferative glomerulonephritis. Nephron 1971;8:67-80.  Back to cited text no. 62  [PUBMED]  
63.Floege J, Eng E, Young BA, Couser WG, Johnson RJ. Heparin suppresses mesangial cell proliferation and matrix expansion in experimental mesangio-proliferative glomerulonephritis. Kidney Int 1993;43:369-80.  Back to cited text no. 63  [PUBMED]  
64.Yokokawa K, Tahara H, Kohno M, Mandal AK, Yanagisawa M, Takeda T. Heparin regulates endothelium production through endothelium-derived nitric oxide in human endothelial cells. J Clin Invest 1993;92:2080-5.  Back to cited text no. 64  [PUBMED]  [FULLTEXT]

Top
Correspondence Address:
E Nigel Wardle
21, Common Road, North Leigh, Oxford OX8 6RD, England
United Kingdom
Login to access the Email id


PMID: 18583745

Rights and Permissions


    Figures

  [Figure - 1], [Figure - 2], [Figure - 3]
 
 
    Tables

  [Table - 1], [Table - 2]



 

Top
 
 
    Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
  Related articles
    Email Alert *
    Add to My List *
* Registration required (free)  
 


 
    Abstract
    Glomerulonephrit...
    Proteinuria
    Phospholipid Der...
    The Prostaglandins
    Thromboxane A2
    Platelet Activat...
    The Leukotrienes
    The HETE (Hydrox...
    The Lipoxins
    The Role of Endo...
    Nitric Oxide
    The Therapy of N...
    Reducing Proteinuria
    Anti-PAF Agents ...
    Thromboxane Anta...
    Vasculitis with ...
    Other Considerat...
    References
    Article Figures
    Article Tables
 

 Article Access Statistics
    Viewed2162    
    Printed74    
    Emailed0    
    PDF Downloaded235    
    Comments [Add]    

Recommend this journal